This activity was originally presented as a part of Psychiatry Day of Education 2025.
Program Description
Tardive dyskinesia (TD) is a movement disorder caused by prolonged use of dopamine receptor-blocking agents, such as antidepressants or antipsychotics. TD remains underdiagnosed and is often irreversible, so minimizing the risk is the first step. Prevention strategies are difficult because patients require long-term medication use to manage chronic psychiatric conditions. Research into hyperkinetic movement disorders has identified VMAT2 inhibitors, which have been shown to deplete dopamine, and these therapies are recognized within guidelines as first-line therapies for the treatment of TD. This activity will focus on risk factors, clinical presentation, and disease burden of TD as well as strategies for pharmacists to identify patients at higher risk for TD and support appropriate medication use and adherence in TD.
Target audience: Ambulatory Care Pharmacist, Consultant Pharmacist, Health System Pharmacist, Specialty Pharmacist
Type of activity: Application
Release date: July 22, 2025
Expiration date: July 22, 2026
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the quality of life burden of tardive dyskinesia (TD) and the unmet clinical need
- Explain treatment guidelines and evidence-based data for VMAT2 inhibitor use in the management of TD
- Analyze pharmacist-led interventions to address barriers to medication adherence, including cost, adverse effects, and stigma associated with TD treatments
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here